Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-815-1 | CAS number: 110-91-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Additional information
In several subchronic and subacute studies no apparent adverse effects on reproductive organs were observed in rats (Conaway et al., 1984; Sander & Bürkle, 1969; Shea, 1939). Inhalation exposure of rats to 900 mg/m³ for 13 weeks resulted in inflammation in mouth and nose; after 7 weeks, focal metaplasia and necroses in nose muscles of 8/40 animals were seen; these findings were intensified after 13 weeks and lesions of chronic murine pneumonia were registered. Organs and tissues examined at necropsy included brain, adrenals, lungs, heart, liver, spleen, kidneys, testes, ovaries, and nasal cavity (Conaway et al. 1984).
In a subchronic trial on rats damage to liver, kidneys and stomach mucosa first appeared after intake of approx. 160 mg/kg bw (Shea, 1939). Observations of rats treated with 800 mg/kg bw included lethargy, weight loss, intense irritation of the intestinal tract, and congestion of the stomach wall and membrane. Microscopic changes in the liver included cloudy swelling, marked congestion, haemorrhage, necrosis, and an increase in Kupffer and connective tissue cells. The kidneys had tubular congestion, degeneration, swelling and necrosis; desquamation of the epithelium also was noted. The spleens of the 800 mg/kg bw group had congestion and showed an increase in splenocytes and hemosiderin deposits. Necrosis of the epithelium and capillary congestion were observed in the stomach. The lungs had congestion and alveolar desquamation. Intake of 800 mg/kg bw caused the death of 10 out of 20 rats within 20 days. At the end of 30 days, only 1 rat was still alive.
Sander & Bürkle (1969) added Morpholine to feed for eight weeks. Seven rats took in a daily average of 500 mg/kg bw. This dosage did not kill the animals. After 270 days had elapsed, the only symptom noted was moderate adiposis of the liver. Damage caused by subchronic oral intake of Morpholine depended markedly on the individual dose and route of administration.
Due to its corrosivity, Morpholine treatment resulted in irritation and inflammation of the upper digestive tract on oral intake, irritation of the respiratory tract and eyes on being inhaled and, in high concentrations, irritation on contact with the skin. Possible target organs of chronic intoxication were the liver, kidneys and stomach.
Because of a high correlation, histopathology data and organ weights from repeated dose studies were used to assess male fertility (Mangelsdorf, 2003). These parameters, taken from 90 day studies, were in fact shown to be more sensitive than fertility parameters that were measured during multi-generation studies. It could also be shown that exposure for 4 weeks suffices for an assessment of male fertility, although 90 day studies have been regarded as superior in the past because they cover a complete cycle of spermatogenesis (Mangelsdorf, 2003). If such a 28 day study shows neither relevantly elevated testis or ovary weights nor histopathological alterations in those organs, the weight of the evidence is that effects on reproduction are also not expected (BAuA, 2003). A comparison of more than one hundred 90 day studies with two-generation studies that used the same test substance additionally showed that the NOAELs differed by less than the variation limit of studies, i.e. a factor of two (Janer, 2007).
Based on the argumentation of Mangelsdorf (2003), the information gained from a two-generation study can be regarded as minimal if a 90 day study has been performed. Thus, based on the data presented for Morpholine, information gained from a two-generation study are regarded as not necessary with regard to the fact that REACH allows the assessment of the reproductive toxicity of a given chemical with the help of findings from studies with repeated administration. This is in line with the idea that the information requirements under REACH are regarded as the evaluation of endpoints which does not necessarily require data from specific studies.
Short description of key information:
Since REACH allows the assessment of the reproductive toxicity of a given chemical with the help of findings from studies with repeated administration, studies available for Morpholine were incorporated to elucidate effects on fertility. No apparent adverse effects on reproductive organs were observed in rats in several subchronic and subacute studies with Morpholine.
Effects on developmental toxicity
Description of key information
In a developmental toxicity study with Morpholine hydrochloride (97 % ) at doses of 75, 250 and 750 mg/kg bw/d applied orally to rats, no adverse fetal findings of toxicological relevance were evident. The developmental NOAEL was determined as 750 mg/kg bw/day, whereas the maternal NOAEL was 75 mg/kg body weight/day based on statistically significant haematological changes in the dams at 250 and 750 mg/kg bw/day.
Effect on developmental toxicity: via oral route
- Dose descriptor:
- NOAEL
- 750 mg/kg bw/day
Additional information
Listed as read across study, Morpholine hydrochloride (97% a.i.) was administered as an aqueous solution to 25 time-mated female Wistar rats (Crl:WI[Han]) by gavage at doses of 75, 250 or 750 mg/kg bw/day on gestation days 6 through 19 in a developmental toxicity study. The control group, consisting of 25 females, was dosed with the vehicle (drinking water) in parallel. A standard dose volume of 10 mL/kg bw was used for each test group. At terminal sacrifice on GD 20, all females (25 per group) had implantation sites. The oral administration of 250 and 750 mg/kg bw/d caused a mild, regenerative anaemia in the dams, along with increased liver weights. Additionally, transiently reduced mean food consumption and bw gain as well as affection of liver cells and liver cell metabolism were noted at high dose. The oral administration of Morpholine hydrochloride to the dams up to 750 mg/kg bw/d had no influence on gestational parameters. Conception rate, mean number of corpora lutea, total implantations, resorptions and live foetuses, foetal sex ratio, and the values calculated for pre- and postimplantation losses were all unaffected. The maternal NOAEL was 75 mg/kg bw/day based on statistically significant haematological changes in the dams at 250 and 750 mg/kg bw/day. Foetal examinations revealed no influence of Morpholine hydrochloride on sex distribution of the foetuses and foetal body weights. Morpholine hydrochloride showed no direct and specific effect on the respective morphological structures. Foetal findings in this study were primarily limited to a slight increase in delayed ossification in the mid- and high-dose groups. These specific skeletal variations mirrored common minor effects on foetal morphology which are considered to be transient in nature, being obviously secondary to maternal toxicity. Thus, these findings were regarded to be of no toxicological relevance and were not classified as adverse events. The developmental NOAEL was 750 mg/kg bw/day. No adverse foetal findings of toxicological relevance were evident at any dose.The developmental toxicity study is classified as acceptable and satisfies the guideline requirement for a developmental toxicity study (OECD 414) in rat.
Justification for classification or non-classification
Classification, Labeling, and Packaging Regulation (EC) No 1272/2008
Since morpholine hydrochloride caused no developmental toxicity and teratogenicity in the rat in a developmental toxicity study according to OECD TG 414 and no apparent adverse effects on reproductive organs or fertility were observed in rats in several subchronic and subacute studies with morpholine, morpholine is considered not to cause damage to the unborn child and is not subject to classification according to Directive 67/548/EEC and Regulation 1272/2008/EC.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live2